Callan Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Callan Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$601K	Sell	11,700 -300	-3%	-$14.8K	0.04%	181
2024 Q4	$664K	Sell	12,000 -3,400	-22%	-$154K	0.05%	142
2024 Q3	$507K	Buy	15,400 +600	+4%	+$16.9K	0.04%	173
2024 Q2	$402K	Buy	14,800 +800	+6%	+$26.9K	0.03%	189
2024 Q1	$509K	Sell	14,000 -2,950	-17%	-$86.7K	0.04%	140
2023 Q4	$343K	Buy	16,950 +1,750	+12%	+$29.2K	0.03%	163
2023 Q3	$270K	Buy	15,200 +450	+3%	+$7.96K	0.03%	167
2023 Q2	$267K	Buy	14,750 +450	+3%	+$7.15K	0.03%	151
2023 Q1	$180K	Buy	14,300 +2,700	+23%	+$39.5K	0.02%	173
2022 Q4	$170K	Buy	+11,600	New	+$192K	0.02%	178

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Callan Capital's TARS Position: Q1 2025 in Review

Callan Capital reduced its Tarsus Pharmaceuticals (TARS) stake by 2.5% in Q1 2025, selling an estimated $14.8K and leaving 11,700 shares worth $601K. The position accounts for 0.04% of the portfolio, ranked #181.

Callan Capital first reported a position in TARS in Q4 2022 and has held it in 10 quarters since. The position peaked at $664K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Callan Capital held 11,700 shares of Tarsus Pharmaceuticals worth $601K as of Q1 2025.
Callan Capital sold 300 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $14.8K.
Tarsus Pharmaceuticals made up 0.04% of Callan Capital's portfolio in Q1 2025, its #181 holding.
Callan Capital first reported a position in Tarsus Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
Callan Capital's Tarsus Pharmaceuticals position peaked at $664K in Q4 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.